Business
Grant of Options
CRISM Therapeutics Corporation announced on June 30, 2026, the grant of options under its EMI Share Option Plan to directors Andrew Webb, Chris McConville, and Gerry Beaney. Andrew Webb received options for 504,000 ordinary shares at an exercise price of 10p, Chris McConville for 408,798 shares at 10p, and Gerry Beaney for 99,999 shares at 10p. These options will vest over two years, with one-third vesting on grant, one-third on the first anniversary, and one-third on the second anniversary, becoming exercisable on the second anniversary and expiring in June 2036. Disclaimer*
About this update from Crism Therapeutics Corporation
30 June 2026 CRISM Therapeutics Corporation ('CRISM', 'CRISM Therapeutics' or the 'Company') Grant of Options CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that it has granted options over ordinary shares of no par value ('Ordinary Shares') in the Company (the 'Options') on 30 June 2026 to certain directors as set out below. Director Total number of Ordinary Shares subject to option grant Options exercise price Vesting Period Andrew Webb 504,000 10p 30 June 2026 - 30 June 2028 Chris McConville 408,798 10p 30 June 2026 - 30 June 2028 Gerry Beaney 99,999 10p 30 June 2026 - 30 June 2028 The awards have been made under the Company's existing EMI Share Option Plan. The Options will vest as to one-third on grant, one-third on the first anniversary of grant and one-third on the second anniversary of grant. The options will become exercisable on the second anniversary of grant and expire on 30 June 2036, being 10 years from the date of grant. The grant of Options to the Executive directors was overseen by the Remuneration Committee which made recommendations to the Board based on its assessment of each executive's personal performance during 2025 and 2026. - Ends - Enquiries: Company Nomad and Broker Financial PR CRISM Therapeutics Corporation S.P. Angel Corporate Finance LLP Burson Buchanan Andrew Webb, Executive Chairman Chris McConville, CSO David Hignell Vadim Alexandre Adam Cowl Henry Harrison Topham Jamie Hooper [email protected] via Burson Buchanan +44 (0) 20 3470 0470 +44 (0) 20 7466 5000 About CRISM Therapeutics Corporation CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implan...
View stock analysis, news, and events for Crism Therapeutics Corporation